Research progress in human immunodeficiency virus entry inhibitors
10.3760/cma.j.cn112866-20250728-00158
- VernacularTitle:人类免疫缺陷病毒进入抑制剂的研究进展
- Author:
Jiewei SUN
1
;
Lei JI
1
;
Ning DING
1
;
Bin SU
1
Author Information
1. 首都医科大学附属北京佑安医院 感染性疾病临床研究中心 中法艾滋病研究联合实验室，北京 100069
- Publication Type:Journal Article
- Keywords:
Human immunodeficiency virus（HIV）;
Entry inhibitors;
Envelope proteins;
Host receptors
- From:
Chinese Journal of Experimental and Clinical Virology
2025;39(5):638-644
- CountryChina
- Language:Chinese
-
Abstract:
Human immunodeficiency virus（HIV）entry inhibitors are important in preventing HIV infection by specifically targeting viral envelope proteins（gp120/gp41）or host receptors（CD4/CCR5/CXCR4）to inhibit HIV entry into host cells. This article systematically reviews the research progress of HIV entry inhibitors in recent years，and some of the novel inhibitors such as Fostemsavir，Ibalizumab，and bifunctional fusion inhibitors（2P23-iMab）have shown better effects in inhibiting multidrug-resistant strains. Although great progress has been made in the research and development of HIV entry inhibitors，there are still a series of challenges including drug resistance，drug limitation，target toxicity，which limit their widespread clinical application. Future research directions should focus on multi-target combination strategies，broad-spectrum neutralizing antibody development，and long-term design. In summary，the analyses on the research progress，challenges and future development directions of HIV entry inhibitors will provide a reference for the further research and development and optimization of HIV entry inhibitors，and then promote the development of AIDS prevention and control.
